At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02637 HAIXI PHARMA
Not Yet Opened 05-05 16:08:12
244.200
-10.000
-3.93%
High268.800
Low244.000
Vol23.70K
Open254.200
D1 Closing254.200
Amplitude9.76%
Mkt Cap19.22B
Tradable Cap19.22B
Total Shares78.71M
T/O6.02M
T/O Rate0.03%
Tradable Shares78.71M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Stock Track | Haixi Pharma Soars 5.74% Intraday on Strong Annual Results and Broker Buy Rating
Fujian Haixi Innovative Drug Development Co., Ltd. was established on March 27, 2012. The company is a commercial-stage pharmaceutical firm that integrates R&D, manufacturing and sales capabilities, and maintains a pipeline of innovative drug candidates. It owns a diversified product portfolio and pipeline across China’s largest and fastest-growing therapeutic areas. As of the latest practicable date, its commercialized portfolio consists mainly of generics for digestive, cardiovascular, endocrine, neurological and inflammatory diseases. According to CIC, these therapeutic areas accounted for over 25 % of China’s total pharmaceutical sales in 2023. The company’s innovative pipeline focuses on drug candidates for multiple indications, including a potential first-in-class oncology asset, a potential first-in-class oral therapy for wet age-related macular degeneration (wAMD) / diabetic macular edema (DME) / retinal vein occlusion (RVO), and two additional pre-clinical-stage innovative programs for oncology and respiratory diseases. All innovative drug candidates are developed and advanced internally through proprietary technologies.